首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

2030 年歐洲生物學名藥市場預測 - 按疾病適應症、給藥途徑、藥物類別、配銷通路和地區進行區域分析

市場調查報告書

商品編碼

1347207

2030 年歐洲生物學名藥市場預測 - 按疾病適應症、給藥途徑、藥物類別、配銷通路和地區進行區域分析

Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication, Route of Administration, Drug Class, Distribution Channel, and Region

出版日期: 2023年08月04日 | 出版商:

The Insight Partners | 英文 205 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

歐洲生物學名藥市場預計將從2022年的103.4486億美元成長到2030年的1151.2591億美元；預計2022年至2030年年複合成長率為35.1%。

該報告重點介紹了市場的普遍趨勢以及推動市場成長的因素。市場成長歸因於慢性病患病率的增加和生物學名藥批准量的增加。此外，在預測期內，生物學名藥和臨床試驗的合作可能會成為市場的一個重要趨勢。然而，生物學名藥產品製造的高成本投入和複雜性阻礙了 2022-2030 年預測期內的市場成長。

生物學名藥和臨床試驗的合作推動歐洲生物學名藥市場

合資企業和其他合作模式將幫助生物學名藥製造商在未來幾年保持相對於市場競爭對手的競爭優勢。

通過與其他計劃研究、推出和銷售生物學名藥的公司合作，生物學名藥製造商可以快速開發產品並有效地推出產品，從而克服專利風險並贏得臨床醫生和患者對產品的信心。通過獲得本地和國外的專業知識、開發平台訪問以及研究和臨床試驗資金，可以加快產品開發。

與更大的生物製藥製造商合作可以使用現有的生產設施。這種合作可以針對外包活動，例如細胞系開發、生物製品和生物學名藥製造、工藝擴展以及任何所需的技術轉讓。

合作可以帶來長期利益。它們可以使國內未來生物學名藥生產項目的招標變得容易，並提供早期、高效的產品開發和市場滲透。在像歐洲這樣的龐大市場中，國家層面的醫療政策和市場動態存在顯著差異，通過此類合作獲得的當地知識也被證明是無價的。

生物學名藥市場的巨大潛力催生了許多近期備受矚目的合作。下面舉幾個例子：

2023 年 6 月，三星生物製劑宣布與輝瑞建立戰略合作夥伴關係，以實現輝瑞多產品組合的長期商業化生產。該協議旨在三星生物製品將為輝瑞提供額外的產能，以大規模生產涵蓋腫瘤學、炎症和免疫學的多產品生物學名藥組合。

2023 年 5 月，諾華子公司 Sandoz 宣布與 Evotec Biologics 開展生物學名藥合作。該協議涵蓋開發和製造多種生物學名藥，旨在快速開發和隨後製造多種生物學名藥。在未來 12-18 個月的合作下，Evotec Biologics 工廠的生物學名藥開發將加快。

因此，生物學名藥生產和臨床試驗製造商的合作將成為預測期內生物學名藥市場的主要趨勢。

重磅生物製劑的專利到期提供了利潤豐厚的市場機會

生物製品代表了治療以前無法治癒的疾病的有前途的新療法，並且在藥品市場中變得非常重要。然而，原研生物製品的專利預計將在未來幾年到期。

下表列出了最暢銷生物製品的預計專利和獨占權到期日。

生物製品到期月份和年份

阿瓦斯汀 2022 年 1 月

西拉姆扎 2023 年 5 月

Adcetris 2023 年 8 月

阿布特拉克斯 2024 年 10 月

加濟瓦/加濟瓦羅 2024 年 11 月

達扎萊克斯 2026 年 5 月

奧克雷烏斯 2027 年 4 月

Emgality 2028 年 9 月

赫姆利布拉 2028 年 2 月

盧梅特里 2028 年 3 月

伊姆芬齊 2028 年 9 月

邁洛塔格 2028 年 4 月

伊姆芬齊 2028 年 9 月

邁洛塔格 2028 年 4 月

西爾萬特 2034 年 7 月

資料來源：學名藥和生物學名藥計劃 (GaBI) 雜誌

原研生物製品的專利到期和其他知識產權將在未來產生推出新生物學名藥的需求。因此，未來幾年該行業市場參與者之間的競爭將加劇。因此，重磅生物製劑的專利到期預計將在預測期內為生物學名藥市場創造利潤豐厚的機會。

2022-2030 年，德國在歐洲生物學名藥市場佔據最大市場佔有率。生物學名藥引入了競爭並提高了生物製劑的可承受性，最終提供節省成本和增值服務來支持患者護理和醫療保健社區。醫療保健專業人員可以用高品質的生物製劑治療更多患者，同時減少支出。例如，在德國，根據 Sandoz 的數據，2022 年推出生物學名藥後，抗 TNF 藥物的每日治療劑量數量增加了 29%（從 17.18 至 2218 萬）。

德國已獲得付款人、提供者和患者的認可，將生物學名藥作為適當藥物使用的一個組成部分。根據公司設定的價格全額報銷，包括患者立即獲得生物學名藥。由多個採購集團和獨立醫院連鎖機構進行的醫院招標結構使得德國製造商之間的競爭得以維持。例如，2018年11月，德國衛生部提出了藥品供應安全法案草案。 Gesetz Fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) 法案旨在為德國藥劑師自動替代生物學名藥提供法律框架。

由於節省成本的巨大潛力，德國衛生部訂定了一項新法律來增加生物學名藥的採用。由於很少有歐盟 (EU) 國家允許藥劑師替代生物學名藥，這將代表實踐中的重大變化，特別是對德國而言。此外，在德國，2019 年通過的一項法律預計，從2022 年開始，藥房將自動替代生物學名藥，前提是聯邦聯合委員會（健康保險公司和醫療服務提供者自治的最高決策機構）已確定生物學名藥的互換性。所涉及的藥物，並且處方醫生沒有明確排除該藥物。因此，隨著德國政府擴大採用生物學名藥，市場預計將會成長。

歐洲生物學名藥市場上的公司採用了各種有機和無機策略。有機戰略主要包括產品發布和產品批准。此外，市場上出現的無機成長策略包括收購、合作和夥伴關係。這些成長戰略使市場參與者能夠擴大業務並增強其地域影響力，從而促進整體市場的成長。此外，收購和合作戰略有助於市場參與者加強其客戶群並擴大其產品組合。下面列出了歐洲生物學名藥市場主要參與者的一些重大進展。

國際糖尿病聯盟、歐洲藥品管理局、疾病預防控制中心、中國臨床腫瘤學、國家綜合護理網路是在準備歐洲生物學名藥市場報告時提到的一些主要的一手和二手來源。

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.

In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12-18 months.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .

Biologicals Expiry Month & Years

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

Source: Generics and Biosimilars Initiative (GaBI) Journal

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.

International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biosimilars market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global Europe biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Europe Biosimilars Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Biosimilars Market - Market Landscape

4.1 Overview
- 4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
- 4.2.1 France
- 4.2.2 Germany
- 4.2.3 Italy
- 4.2.4 Spain
- 4.2.5 UK

5. Europe Biosimilars Market

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
- 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
- 5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
- 5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis

6. Europe Biosimilars Market - Regional Analysis

6.1 Europe Biosimilars Market Revenue Forecast and Analysis

7. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Disease Indication

7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
- 7.4.1 Overview
- 7.4.2 Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
- 7.5.1 Overview
- 7.5.2 Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.3 Psoriasis
  - 7.5.3.1 Overview
- 7.5.4 Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.5 Arthritis
  - 7.5.5.1 Overview
- 7.5.6 Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.7 Others
  - 7.5.7.1 Overview
  - 7.5.7.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
- 7.6.1 Overview
- 7.6.2 Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration

8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
- 8.3.1 Overview
- 8.3.2 Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
- 8.4.1 Overview
- 8.4.2 Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Drug Class

9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
- 9.3.1 Overview
- 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
- 9.4.1 Overview
- 9.4.2 Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
- 9.5.1 Overview
- 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Distribution Channel

10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
- 10.3.1 Overview
10.4 Immunologists
- 10.4.1 Overview
10.5 Rheumatologists
- 10.5.1 Overview
10.6 Oncologists
- 10.6.1 Overview
10.7 Dermatologists
- 10.7.1 Overview
10.8 Retina Compounding
- 10.8.1 Overview
10.9 Others
- 10.9.1 Overview
10.10 Hospital Pharmacies
- 10.10.1 Overview
- 10.10.2 Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.3 Endocrinologists
  - 10.10.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.4 Immunologists
  - 10.10.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.5 Rheumatologists
  - 10.10.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.6 Oncologists
  - 10.10.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.7 Dermatologists
  - 10.10.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.8 Retina Specialists
  - 10.10.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.9 Others
  - 10.10.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
- 10.11.1 Overview
- 10.11.2 Compounding Pharmacies : Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.3 Endocrinologists
  - 10.11.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.4 Immunologists
  - 10.11.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.5 Rheumatologists
  - 10.11.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.6 Oncologists
  - 10.11.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.7 Dermatologists
  - 10.11.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.8 Retina Specialists
  - 10.11.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.9 Others
  - 10.11.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
- 10.12.1 Overview
- 10.12.2 Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.3 Endocrinologists
  - 10.12.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.4 Immunologists
  - 10.12.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.5 Rheumatologists
  - 10.12.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.6 Oncologists
  - 10.12.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.7 Dermatologists
  - 10.12.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.8 Retina Specialists
  - 10.12.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.9 Others
  - 10.12.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
- 10.13.1 Overview
- 10.13.2 Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.3 Endocrinologists
  - 10.13.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.4 Immunologists
  - 10.13.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.5 Rheumatologists
  - 10.13.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.6 Oncologists
  - 10.13.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.7 Dermatologists
  - 10.13.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.8 Retina Specialists
  - 10.13.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.9 Others
  - 10.13.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Biosimilars Market - Revenue and Forecast to 2030 - Geographic Analysis

11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
  - 11.1.2.1 Europe Biosimilars Market, by Disease Indication
  - 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
  - 11.1.2.3 Europe Biosimilars Market, by Route of Administration
  - 11.1.2.4 Europe Biosimilars Market, by Drug Class
  - 11.1.2.5 Europe Biosimilars Market, by Distribution Channel
  - 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
  - 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
  - 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
  - 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
  - 11.1.2.10 Europe Biosimilars Market by Country
    - 11.1.2.10.1 Germany
    - 11.1.2.10.1.1 Overview
    - 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
    - 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
    - 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
    - 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
    - 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.2 UK
    - 11.1.2.10.3 Overview
    - 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
    - 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
    - 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
    - 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
    - 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.4 France
    - 11.1.2.10.4.1 Overview
    - 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
    - 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
    - 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
    - 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
    - 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.5 Italy
    - 11.1.2.10.5.1 Overview
    - 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
    - 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
    - 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
    - 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
    - 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.6 Spain
    - 11.1.2.10.6.1 Overview
    - 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
    - 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
    - 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
    - 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
    - 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.7 Rest of Europe
    - 11.1.2.10.7.1 Overview
    - 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
    - 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
    - 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
    - 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
    - 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies

12. Pre and Post COVID-19 Impact

12.1 Pre and Post COVID-19 Impact

13. Biosimilars Market - Industry Landscape

13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
14.4 Biocon Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Eli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Comparison Between Different Drug Developments
Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 66. Recent Organic Growth Strategies in Biosimilars Market
Table 67. Glossary of Terms

List Of Figures

Figure 1. Biosimilars Market Segmentation
Figure 2. Biosimilars Market, by Region
Figure 3. Key Insights
Figure 4. Europe: PEST Analysis
Figure 5. Europe Biosimilars Market- Key Industry Dynamics
Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
Figure 7. Europe Biosimilars Market - Revenue Forecast and Analysis - 2020-2030
Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
Figure 9. Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
Figure 17. Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 26. Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. Compounding Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 35. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 36. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 38. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 39. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 40. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 41. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 42. Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 43. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 44. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 45. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 46. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 47. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 48. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 49. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 50. Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 52. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 53. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 54. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 55. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 56. Retina Compounding: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 57. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
Figure 68. Growth Strategies in Biosimilars Market